Details of the Drug Formulations

General Information of Drug (ID: DM6T2J3)

• Drug Name: Neostigmine Drug Info
• Synonyms: Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Approved	[1]
Urinary retention	MF50.3	Approved	[2]

• Therapeutic Class: Parasympathomimetics
• Cross-matching ID:
  PubChem CID: 4456
  ChEBI ID: CHEBI:7514
  CAS Number: 59-99-4
  TTD ID: D08USJ
  VARIDT ID: DR01375
  ACDINA ID: D01279

Full List of Drug Formulations Containing This Drug

Neostigmine 3mg/3ml solution

Company	Formulation ID	FDA Description
Fresenius Kabi Usa	F24092	Phenol; Sodium Acetate Trihydrate; Water For Injection

Neostigmine 5mg/10ml solution

Company	Formulation ID	FDA Description
Exela Pharma; Fresenius Kabi Usa	F24279	Phenol; Sodium Acetate Trihydrate; Water For Injection

Neostigmine 10mg/10ml solution

Company	Formulation ID	FDA Description
Exela Pharma; Fresenius Kabi Usa	F24280	Phenol; Sodium Acetate Trihydrate; Water For Injection

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Neostigmine FDA Label